Behavioral
Owensboro Health Medical Group, INC.
Owensboro Health Medical Group, INC. was paid $3.06M by Medicaid between Jan 2018 and Dec 2024, across 68 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoOWENSBORO HEALTH MEDICAL GROUP, INC.
POWDERLY, KY 42367
POWDERLY, KY 42367
33aNPI1770001877assigned 09/08/2017
33bProvider typeProfessional Counselor
28Total paid$3.06M
24GClaims102,998
24DCodes billed68
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Professional Counselor providers in Kentucky
Rank by total paid#28 of 255
Median peer was paid$129K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RANALLO, RUSSELL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,051 | $254K | |
| 2019 | 10,263 | $283K | |
| 2020 | 6,767 | $172K | |
| 2021 | 11,345 | $270K | |
| 2022 | 16,632 | $426K | |
| 2023 | 24,173 | $784K | |
| 2024incomplete | 24,767 | $874K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 35,917 | 32,910 | $1.02M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 9,274 | 8,756 | $417K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 9.4% | 2,771 | 2,706 | $287K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.8% | 3,573 | 3,320 | $269K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.2% | 6,483 | 6,221 | $190K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.6% | 5,597 | 5,223 | $140K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.7% | 1,862 | 1,813 | $114K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.9% | 1,648 | 1,548 | $89K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 4,852 | 4,397 | $64K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 585 | 575 | $62K |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 5,024 | 4,683 | $60K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 1,446 | 1,414 | $51K |
56 more codes
| 99204 | Doctor's office visit, new patient (more involved) | 1.4% | 483 | $44K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.4% | 3,380 | $43K |
| 87634 | 1.0% | 546 | $32K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,184 | $18K |
| 87807 | <1% | 1,401 | $16K | |
| 74018 | <1% | 1,269 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,784 | $14K |
| 20610 | <1% | 371 | $14K | |
| 73630 | <1% | 979 | $12K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 375 | $8K |
| 73610 | <1% | 591 | $7K | |
| 73030 | <1% | 562 | $7K | |
| 73564 | <1% | 427 | $6K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 99 | $6K |
| 71271 | <1% | 107 | $6K | |
| 73110 | <1% | 468 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 553 | $5K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 25 | $5K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 680 | $4K |
| 73130 | <1% | 307 | $4K | |
| 72110 | <1% | 181 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 103 | $3K |
| 90461 | <1% | 92 | $3K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 46 | $3K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 45 | $3K |
| 99243 | <1% | 32 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 67 | $2K |
| 73562 | <1% | 145 | $2K | |
| 72100 | <1% | 100 | $1K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 270 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 61 | $1K |
| 77080 | <1% | 24 | $1K | |
| 81003 | <1% | 2,597 | $989.37 | |
| 96127 | <1% | 347 | $967.80 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,047 | $962.34 |
| 90686 | <1% | 45 | $632.03 | |
| 73502 | <1% | 38 | $564.04 | |
| 76642 | <1% | 20 | $467.37 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 18 | $452.23 |
| 76536 | <1% | 14 | $398.99 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 295 | $393.70 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 37 | $284.92 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25 | $213.19 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 18 | $204.02 |
| 81025 | <1% | 37 | $164.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 62 | $138.64 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 38 | $128.62 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 13 | $123.01 |
| 87210 | <1% | 25 | $111.78 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 124 | $40.02 |
| 90670 | <1% | 15 | $36.80 | |
| 90698 | <1% | 12 | $36.80 | |
| 82962 | <1% | 13 | $23.12 | |
| 90633 | <1% | 43 | $18.40 | |
| 90710 | 0% | 12 | $0.00 | |
| 99024 | 0% | 1,314 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRANALLO, RUSSELL (SECRETARY)
Parent organizationOWENSBORO HEALTH, INC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.